Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stake Boosted by Nuveen Asset Management LLC

Nuveen Asset Management LLC grew its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 1.8% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 468,346 shares of the specialty pharmaceutical company’s stock after acquiring an additional 8,448 shares during the period. Nuveen Asset Management LLC’s holdings in Jazz Pharmaceuticals were worth $57,677,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of JAZZ. Fuller & Thaler Asset Management Inc. grew its holdings in shares of Jazz Pharmaceuticals by 117.4% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 939,351 shares of the specialty pharmaceutical company’s stock valued at $115,681,000 after acquiring an additional 507,234 shares in the last quarter. Darwin Global Management Ltd. purchased a new position in shares of Jazz Pharmaceuticals during the 4th quarter valued at $59,668,000. Dimensional Fund Advisors LP grew its holdings in shares of Jazz Pharmaceuticals by 18.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company’s stock valued at $250,619,000 after acquiring an additional 320,724 shares in the last quarter. Ameriprise Financial Inc. grew its holdings in shares of Jazz Pharmaceuticals by 20.9% during the 4th quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company’s stock valued at $225,076,000 after acquiring an additional 315,608 shares in the last quarter. Finally, GMT Capital Corp grew its holdings in shares of Jazz Pharmaceuticals by 140.0% during the 4th quarter. GMT Capital Corp now owns 508,800 shares of the specialty pharmaceutical company’s stock valued at $62,659,000 after acquiring an additional 296,800 shares in the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, EVP Neena M. Patil sold 3,800 shares of the business’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $144.87, for a total transaction of $550,506.00. Following the transaction, the executive vice president now owns 33,318 shares in the company, valued at approximately $4,826,778.66. The trade was a 10.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Seamus Mulligan acquired 100,000 shares of the company’s stock in a transaction dated Friday, May 9th. The shares were bought at an average price of $98.26 per share, for a total transaction of $9,826,000.00. Following the acquisition, the director now owns 100,000 shares in the company, valued at approximately $9,826,000. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 28,236 shares of company stock valued at $3,956,190 in the last quarter. Insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Stock Up 2.7%

Jazz Pharmaceuticals stock opened at $108.98 on Monday. The firm has a market cap of $6.72 billion, a price-to-earnings ratio of 15.35, a P/E/G ratio of 1.04 and a beta of 0.38. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. Jazz Pharmaceuticals plc has a fifty-two week low of $95.49 and a fifty-two week high of $148.06. The firm has a fifty day moving average price of $115.73 and a two-hundred day moving average price of $122.09.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing analysts’ consensus estimates of $4.65 by ($2.97). The firm had revenue of $897.84 million for the quarter, compared to analyst estimates of $984.16 million. Jazz Pharmaceuticals had a return on equity of 29.30% and a net margin of 11.60%. The firm’s revenue was down .5% on a year-over-year basis. During the same period in the prior year, the firm earned $2.68 EPS. As a group, analysts forecast that Jazz Pharmaceuticals plc will post 16.96 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. HC Wainwright boosted their price target on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the company a “buy” rating in a report on Monday, March 10th. UBS Group raised shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $145.00 to $179.00 in a research note on Friday, March 7th. Wells Fargo & Company raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $130.00 to $170.00 in a research note on Thursday, February 13th. Needham & Company LLC reaffirmed a “buy” rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 7th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $182.79.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.